Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 73%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris is a late-stage biopharmaceutical company that focuses on developing novel, oral bradykinin B2 receptor antagonists for the prevention and treatment of hereditary angioedema (HAE). The company's lead asset, deucrictibant, is an oral small molecule that has shown positive results in both Phase 2 prophylaxis and on-demand studies in HAE patients. Compared to currently available therapies, deucrictibant offers a more convenient and discreet oral administration, potentially increasing patient adherence and quality of life. With a strong management team and a growing HAE platform, Pharvaris is well-positioned to capture a share in the HAE market, which is expected to reach ~$4 billion by 2025. The company's ongoing pivotal Phase 3 studies for the treatment and prevention of HAE attacks, as well as its efforts to explore deucrictibant's potential in other types of angioedema, demonstrate its commitment to creating value for patients and investors. Given the positive data and potential of deucrictibant, we believe Pharvaris has strong potential for growth and market success.

Bears say

Pharvaris is currently facing multiple challenges with their late-stage biopharmaceutical product deucrictibant, including a crowded market for HAE treatments and potential safety concerns with liver enzyme elevations. The company's success may also depend on insurance coverage and pricing for their XR formulation. Additionally, their success in the AAE market is not yet proven, and dilutive financing remains a risk. As a result, the financial outlook for Pharvaris is uncertain, and it may not see the same level of success as other treatments in this space.

Pharvaris B.V. (PHVS) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 73% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 11 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.